Search

One of the real threats to the health of the next generation are diseases caused predominantly by sexually transmitted infections (STIs). The frequency of these diseases is constantly increasing among the population of Ukraine and other countries. The aim of our work was to establish the features of the clinical manifestations of diseases caused by urogenital infections (UGI) at the present stage. Under our supervision, there were 577 patients with STIs, 83% of the patients were at the age of the highest socio-economic and sexual activity. A complex of methods for examining the patients included: physical and general clinical studies, laboratory research to identify STIs and conditionally pathogenic microorganisms. A comprehensive complex examination made it possible to identify urogenital chlamydia in 395 (68.5%), trichomoniasis – in 381 (66.03%), ureaplasmosis – in 240 (41.6%), microorganisms associated with bacterial vaginosis – in 80 (13.9%) and urogenital candidiasis – in 75 (13.0%). Monoinfection was diagnosed only in 61 (10.6%) of patients. Among the patients examined, the inflammatory process of the genitourinary organs was supported by two infectious agents in 487 (84.4%), three or more – in 52 (9.0%) of the observed patients. The affection of the urogenital system with STIs occurs with several infectious agents. Clinical manifestations of diseases caused by STIs are asymptomatic or low-symptomatic. The asymptomatic course of diseases caused by STIs leads to a chronic long-term course of the pathological process with the formation of multi-focal lesions and residual phenomena, including proliferative neoplasms.

The purpose of the work is to evaluate the efficacy and tolerance of extemporal dosage form with pyroctone olamine in the local treatment of patients with seborrheic dermatitis. Under our supervision there were 78 patients with seborrheic dermatitis aged 18 to 57 years. The average age of the patients was 29.5±2.1 years. Comprehensive treatment of patients with seborrheic dermatitis in both groups depended on the severity of clinical manifestations, the duration of the disease, and information on the effectiveness of previous therapy. For external treatment of the main group of patients with seborrheic dermatitis, an extemporaneously prepared gel with pyrocton olamine was used. Local treatment of patients in the comparison group consisted of the appointment of 1% cream of clotrimazole. An analysis of the results shows good therapeutic, microbiological effectiveness and good tolerance of extemporaneously prepared gel with pyrocton olamine in the complex treatment of patients with seborrheic dermatitis. The period for resolving the clinical manifestations of seborrheic dermatitis among patients in the main group was 2.5±0.1 days shorter compared with patients in the comparison group. The intensity of clinical manifestations in patients with seborrheic dermatitis of the main group decreased twice on the second day of complex treatment. In control patients with comparative seborrheic dermatitis, similar therapeutic efficacy was achieved on the fourth to fifth day. Long-term results of the study showed that the recurrence of the disease among patients of the main group was 5 (6.4%), and in patients of in the comparison group was 14 (17.9%). Clinical studies have shown good therapeutic efficacy and tolerance of the extemporal gel with pyroctone olamine in the complex treatment of patients with seborrheic dermatitis, which gives reason to recommend this dosage form for wider use in the practice of dermatovenerologists.

According to the European and American authors the onychomycosis prevalence in the world has amount from 8.0 % to 26.9 %. Topical treatment of onychomycosis in most cases is the only acceptable method of therapy mainly due to high safety. Etiotropic topical pharmacotherapy of this pathology is carried out by the dermatomicotic medicines – creams, ointments, gels, solutions. Nail polishes are the specific dosage forms for onychomycosis therapy. However antimycotic polish therapy is sufficiently effective only in case of treatment the surface white and distal-lateral form of onychomycosis, but just in case when less than 1/3 of nail plate is affected. Also wide application is limited to length of use (from 6 month to 1 year) and high therapy cost. According to above mentioned information, development of specific semisolid dosage form for onychomycosis therapy without removing the nail plate and allowing combination high efficacy of medical substances even in case of nail-bed affection, rational term of treatment and economical availability is rational. Presence of these effects may be reached by the way of combination in semisolid dosage form for appliication on the nail plate – the paste – substances with keratolytic and antimycotic action. At the same time use of acid combination as a keratolytic for pH decreasing in tissue of the nail plate and fungi growth inhibition and also providing with penetration of active components of paste for onychomycosis therapy. As a result of this development of semisolid dosage form for the topical treatment of onychomycosis with biologically active substances from the group of nonspecific antimycotics (2-mercaptobenzthiazol, chinozol) with broad spectrum of antimycotic, antibacterial activity and safety has a scientific and practical interest. The aim of this work is biopharmaceutical substantiation of optimal base for semisolid dosage form – paste for etiotropic therapy of onychomycosis. Materials and methods. As a device for developing pharmacotherapeutical preparation hydrofobic and emulsion bases resistant to combination with sufficiently aggressive keratolytics and described in literature were studied. As an active pharmaceutical ingredient for antimycotic paste 2-mercaptobenzthiazol and chinozol in concentration 10% and 10% accordingly for providing with the optimal level of antifungal activity were used. As keratolytic substances traditionally used for onycholysis: carbamide, mixture of salicylic and benzoic acids in concentration described in literature were used. At the same time chinozol shows keratolytic effect and in that capacity is used in formulations of chinozolo-salicylic, chinozolo-dimexidic and also carbamidic plasters for nails. The content of dry substances and plasticizers in formulations of onycholytic pastes was chosen taking into account the requirements of Ukrainian Pharmacopoea and normative document for this dosage form. Taking into account the advisability of high dispersion degree of medical substances in semisolid dosage forms for external use and physical-chemical properties of 2-mercaptobenzthiazol the latter was added in emulsion bases after preliminary dissolution in polyethylenoxyde 400 with heating. Keratolytics were added as a suspension in all bases. Investigations of scientifically substantiation of the base of paste for onychomycosis therapy were carried out according to plan of single-factor analysis of variance with repeated observations. For all selected compositions the releasing of active pharmaceutical ingredients (2-mercaptobenzthiazol and chinozol) from ointments were studied with equilibrium dialysis method by Kruvchinsky at the temperature 25.0 ± 0.5 °С (temperature on the surface of nail) through the semipermeable film “Kuprofan” in the Franz diffusion cell apparatus (producer PermeGear, Inc., USA). As a dialysis medium taking into account 2-mercaptobenzthiazol solubility was used solution containing methanol and water 1:1 and chinozol releasing was carried out into water. Concentration of active pharmaceutical substances released from experimental pastes after 2 hours was determined spectrophotometrically. Results. Carried out verification of average results of 2-mercaptobenzthiazol and chinozol releasing by the Dunkan’s multiple rank test allowed to build the preferred series of pastes base influence on the intensity of active pharmaceutical ingredients releasing. Obtained results showed the sighnificant advantage of the emulsion ointment base providing with optimal level of 2-mercaptobenzthiazol and chinozol releasing from experimental compositions of semisolid dosge forms for onychomycosis therapy. Conclusions. It was determined that sort of the base makes a sighnificant influence on 2-mercaptobenzthiazol and chinozol releasing from the antimycotic pastes for onychomycosis therapy. Variance analysis of results revealed that emulsion vehicle containing acid-resisting emulsifier provides with optimal 2-mercaptobenzthiazol and chinozol releasing.